Celcuity (NASDAQ:CELC) Sets New 12-Month High – Here’s What Happened

Celcuity, Inc. (NASDAQ:CELC)’s share price hit a new 52-week high on Thursday . The stock traded as high as $104.81 and last traded at $104.4960, with a volume of 189091 shares trading hands. The stock had previously closed at $100.00.

Analysts Set New Price Targets

A number of research firms have commented on CELC. Craig Hallum increased their target price on Celcuity from $96.00 to $108.00 and gave the stock a “buy” rating in a report on Thursday, November 13th. HC Wainwright reissued a “neutral” rating and set a $94.00 price target (up from $77.00) on shares of Celcuity in a research report on Monday, November 17th. Wolfe Research began coverage on shares of Celcuity in a report on Tuesday, November 18th. They issued an “outperform” rating and a $110.00 price objective for the company. Guggenheim began coverage on shares of Celcuity in a research note on Monday, September 22nd. They set a “buy” rating for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Celcuity in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $102.29.

Celcuity Stock Up 5.3%

The company has a current ratio of 12.26, a quick ratio of 12.26 and a debt-to-equity ratio of 2.74. The firm has a market cap of $4.87 billion, a price-to-earnings ratio of -28.69 and a beta of 0.21. The stock has a 50-day moving average of $72.56 and a 200-day moving average of $44.84.

Celcuity (NASDAQ:CELC) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.92) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.05) by $0.13. As a group, sell-side analysts forecast that Celcuity, Inc. will post -2.62 EPS for the current fiscal year.

Insider Buying and Selling at Celcuity

In related news, Director Richard E. Buller sold 3,900 shares of the firm’s stock in a transaction dated Thursday, November 20th. The stock was sold at an average price of $96.73, for a total transaction of $377,247.00. Following the completion of the transaction, the director owned 7,260 shares of the company’s stock, valued at $702,259.80. This trade represents a 34.95% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 15.77% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Celcuity

Hedge funds have recently made changes to their positions in the company. US Bancorp DE grew its stake in shares of Celcuity by 25.4% in the 3rd quarter. US Bancorp DE now owns 706 shares of the company’s stock valued at $35,000 after buying an additional 143 shares in the last quarter. Rhumbline Advisers lifted its stake in shares of Celcuity by 1.2% in the 2nd quarter. Rhumbline Advisers now owns 42,697 shares of the company’s stock valued at $570,000 after purchasing an additional 503 shares during the last quarter. Ogorek Anthony Joseph NY ADV acquired a new position in Celcuity during the third quarter worth $27,000. Intech Investment Management LLC raised its holdings in Celcuity by 5.2% during the second quarter. Intech Investment Management LLC now owns 14,855 shares of the company’s stock valued at $198,000 after buying an additional 734 shares in the last quarter. Finally, BNP Paribas Financial Markets lifted its position in Celcuity by 78.9% during the 2nd quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company’s stock worth $35,000 after acquiring an additional 1,167 shares during the last quarter. Hedge funds and other institutional investors own 63.33% of the company’s stock.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.